Focus Financial Network Inc. bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 3,268 shares of the medical equipment provider's stock, valued at approximately $292,000.
Several other institutional investors and hedge funds have also modified their holdings of the business. Janus Henderson Group PLC grew its position in shares of Lantheus by 7.7% in the 3rd quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider's stock valued at $393,844,000 after purchasing an additional 257,022 shares during the period. Geode Capital Management LLC grew its position in shares of Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock valued at $184,798,000 after purchasing an additional 32,551 shares during the period. Reinhart Partners LLC. grew its position in shares of Lantheus by 9.9% in the 4th quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider's stock valued at $122,280,000 after purchasing an additional 123,282 shares during the period. Swedbank AB lifted its stake in Lantheus by 53.3% in the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock valued at $99,054,000 after acquiring an additional 385,000 shares in the last quarter. Finally, Portolan Capital Management LLC lifted its stake in Lantheus by 6.1% in the 3rd quarter. Portolan Capital Management LLC now owns 670,881 shares of the medical equipment provider's stock valued at $73,629,000 after acquiring an additional 38,776 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Lantheus
In related news, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.50% of the company's stock.
Lantheus Trading Up 3.6 %
Shares of Lantheus stock traded up $2.87 on Tuesday, reaching $82.81. 295,778 shares of the company were exchanged, compared to its average volume of 773,905. Lantheus Holdings, Inc. has a one year low of $56.06 and a one year high of $126.89. The company has a market capitalization of $5.76 billion, a price-to-earnings ratio of 13.78 and a beta of 0.44. The company has a 50-day moving average of $91.17 and a 200 day moving average of $97.53.
Wall Street Analysts Forecast Growth
Several research firms have commented on LNTH. The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They issued a "buy" rating and a $143.00 target price on the stock. Truist Financial restated a "buy" rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. StockNews.com cut Lantheus from a "buy" rating to a "hold" rating in a research note on Thursday, November 21st. Finally, JMP Securities restated a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Lantheus presently has an average rating of "Moderate Buy" and an average price target of $131.86.
View Our Latest Report on LNTH
About Lantheus
(
Free Report)
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
Further Reading
Before you consider Lantheus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lantheus wasn't on the list.
While Lantheus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
